Form 4: Rocket Pharmaceuticals Executive's Spouse Buys Shares in Brokered Transactions

Kinnari Patel, President, Head of R&D and COO of Rocket Pharmaceuticals, reports that her spouse purchased 21,099 shares of RCKT common stock in a series of brokered transactions.

Summary

• On April 9, 2025, the spouse of Kinnari Patel, President, Head of R&D and COO of Rocket Pharmaceuticals, purchased 21,099 shares of RCKT common stock.
• The purchases were made in a series of brokered transactions at prices ranging from $4.65 to $4.78 per share, with a weighted average price of $4.70.
• The aggregate purchase price was approximately $99,157.
• Following the transaction, Ms. Patel indirectly owns 26,774 shares through her spouse and directly owns 444,103 shares, and indirectly owns 104,927 shares through Adaptive Technology LLC.
• These holdings include Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a routine disclosure of an insider's spouse purchasing shares. While it could be seen as a positive signal, it's not a strong indicator on its own.

Positives

• The purchase of shares by an insider's spouse could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity. It's important to monitor such filings to gauge insider sentiment, but a single purchase by a spouse is not necessarily indicative of a major trend.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Insider Trading, Form 4, Kinnari Patel, Stock Purchase, Beneficial Ownership, Adaptive Technology LLC